Innovus Pharmaceuticals (OTCMKTS:INNV) Rating Increased to Sell at ValuEngine

Innovus Pharmaceuticals (OTCMKTS:INNV) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday, February 2nd.

Separately, Zacks Investment Research raised Innovus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 23rd.

Shares of Innovus Pharmaceuticals (OTCMKTS INNV) opened at $0.17 on Friday. The company has a market capitalization of $27.59, a price-to-earnings ratio of -2.80 and a beta of 2.63. Innovus Pharmaceuticals has a fifty-two week low of $0.08 and a fifty-two week high of $0.39.

Innovus Pharmaceuticals (OTCMKTS:INNV) last announced its earnings results on Tuesday, November 14th. The company reported ($0.01) EPS for the quarter. The company had revenue of $2.22 million for the quarter. Innovus Pharmaceuticals had a negative net margin of 102.95% and a negative return on equity of 330.39%. research analysts expect that Innovus Pharmaceuticals will post -0.04 earnings per share for the current year.

WARNING: “Innovus Pharmaceuticals (OTCMKTS:INNV) Rating Increased to Sell at ValuEngine” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at

Innovus Pharmaceuticals Company Profile

Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply